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Abstract Although muscle regeneration after injury is
accompanied by apoptotic cell death, prolonged apoptosis
inhibits muscle restoration. The goal of our study was to
provide evidence that inhibition of apoptosis improves
muscle function following blunt skeletal muscle injury.
Therefore, 24 rats were used for induction of injury to the
left soleus muscle using an instrumented clamp. All ani-
mals received either 3.3 mg/kg i.p. of the pan-caspase
inhibitor Z-valinyl-alanyl-DL-aspartyl-ﬂuoromethylketone
(z-VAD.fmk) (n = 12 animals) or equivalent volumes of
the vehicle solution DMSO (n = 12 animals) at 0 and 48 h
after trauma. After assessment of the fast twitch and tetanic
contraction capacity of the muscle at days 4 and 14 post
injury, sampling of muscle tissue served for analysis of cell
apoptosis (cleaved caspase 3 immunohistochemistry), cell
proliferation (BrdU immunohistochemistry) as well as of
muscle tissue area and myoﬁber diameter (HE planimetric
analysis). Muscle strength analysis after 14 days in the
z-VAD.fmk treated group revealed a signiﬁcant increase in
relative muscle strength when compared to the DMSO
treated group. In contrast to the DMSO treated injured
muscle, showing a transient switch towards a fast-twitching
muscle phenotype (signiﬁcant increase of the twitch-to-
tetanic force ratio), z-VAD.fmk treated animals showed an
enhanced healing process with a faster restoration of the
twitch-to-tetanic force ratio towards the physiological
slow-twitching muscle phenotype. This enhancement of
muscle function was accompanied by a signiﬁcant decrease
of cell apoptosis and cell proliferation at day 4 as well as
by a signiﬁcant increase of muscle tissue area at day 4. At
day 14 after injury z-VAD.fmk treated animals presented
with a signiﬁcant increase of myoﬁber diameter compared
to the DMSO treated animals. Thus, z-VAD.fmk could
provide a promising option in the anti-apoptotic therapy of
muscle injury.
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Introduction
Musculoskeletal diseases and soft tissue traumata are a
major burden on society, representing the most common
cause of pain and impaired function in sports worldwide [1,
2]. From a clinical point of view, muscle injury represents a
serious factor limiting the therapeutic outcome in the ﬁelds
of trauma surgery, transplantation, plastic surgery and
orthopedics.
A crucial requirement for the development of novel
therapeutic strategies after muscle injuries is to understand
how muscle regeneration is regulated and muscle loss
occurs. According to current therapeutic strategies and
daily clinical practice, muscle injuries predominantly heal
with residual deﬁcits since till now no causal treatment
options exist [3]. As a result, complications such as
enduring pain, atrophy and impaired functionality are often
encountered. Several groups have attempted to improve
muscle recovery using a variety of drugs, applying cyto-
kines, transplanting cells or even modifying genes in the
muscle [4, 5]. Unfortunately poor study results or limited
applicability of the methods are indicating that the research
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investigations.
A vital process of muscle regeneration is muscle cell
apoptosis. This mode of cell death occurs normally during
aging [6] and growth [7] of the muscle but also under
pathologic conditions like upon muscle injury [8, 9]o ri n
neuromuscular diseases [10]. Furthermore, programmed
cell death is an important regulatory process for tissue
homeostasis and normal development [11, 12]. Although
muscle regeneration after injury is accompanied by apop-
totic cell death, prolonged apoptosis inhibits muscle res-
toration after trauma [9]. From a cell-biological point of
view, the apoptotic process can be induced by a variety of
pathways, which are mediated by ligands, pro-apoptotic
proteins, reactive oxygen species, cytochrome c or mito-
chondrial proteins like apoptosis inducing factor or endo-
nuclease G [13, 14]. Key proteins during apoptosis are the
members of the caspase family, which regulate apoptosis or
irreversibly induce programmed cell death [14].
The goal of our study was to provide compelling evi-
dence that caspase inhibition via the pan-caspase inhibitor
Z-valinyl-alanyl-DL-aspartyl-ﬂuoromethylketone (z-VAD.
fmk) improves muscle function following blunt skeletal
muscle injury. We hypothesized that animals with a muscle
injury and apoptosis inhibition would beneﬁt by ampliﬁed
muscle function and improved muscle regeneration.
Materials and methods
Animal model
For this purpose 24 juvenile male Wistar rats (300–325 g
body weight (bw), 62–67 days old; Charles River Labo-
ratories, Sulzfeld, Germany) were used for the experiments
and were kept on water and standard laboratory chow
ad libitum. Under pentobarbital sodium anesthesia (55 mg/
kg bw i.p.; Narcoren, Merial, Hallbergmoos, Germany) the
left lower limb was shaved and disinfected with povidone-
iodine. Through a 2 cm posterolateral longitudinal incision
of the skin and the underlying fascia from the lateral gas-
trocnemius head to the Achilles tendon the soleus muscle
was mobilized. The blunt injury was induced on the left
soleus muscle via an instrumented clamp (area of contact
between muscle tissue and clamp: 10 mm
2), which allowed
a standardized force application of 25 N for 10 s (DMC
PLUS, HBM Hottinger Baldwin Messtechnik GmbH Ger-
many). The muscle was manually clamped seven times
over its complete length (total crushed area: 70 mm
2) with
exception of the entry point of the supplying neurovascular
structures, which arise from the mid part of the medial
gastrocnemius [9, 15, 16]. For immunohistochemical
analysis of muscle cell proliferation animals received a
single intraperitoneal injection of BrdU (50 mg/kg -48 h
prior to the ﬁnal experiments at either day 4 or 14 post-
injury), similarly as already described [9, 17, 18].
Muscle strength measurement
For in vivo assessment of muscle strength animals were re-
anesthetized at day 4 and 14 post-injury. After bilateral
exposure of the sciatic nerve and the soleus muscle the
Achilles tendon was cut and the lower extremity was ﬁxed
into the muscle force-measuring device (Experimetria,
Budapest, Hungary). The sciatic nerve was subsequently
stimulated with 9 mA/75 Hz bipolar ﬁve times, 0.1 s (8
periods) with 5 s interval between the pulses. After this fast
twitch stimulation protocol maximal strength was mea-
sured by application of 9 mA/75 Hz pulses for the ﬁve
times, 3 s each with 5 s intervals, reaching tetany in all
cases. Contraction forces under fast twitch and tetanic
stimulation were analyzed by calculating the mean of the
maximal values from ﬁrst ﬁve consecutive contractions and
given as percentage of the corresponding values of the
contralateral non-injured muscle. After completion of
muscle strength measurements experiments were termi-
nated by excision of the injured left soleus muscle for
subsequent histology and immunohistochemistry.
Histology and immunohistochemistry
For immunohistochemical demonstration of BrdU in the
muscle tissue we used a monoclonal mouse anti-BrdU
antibody (1:50; No. M0744, Dako Cytomation, Hamburg,
Germany). 3,30-diaminobenzidine was used as chromogen.
Sections were analyzed by light microscopy (BX 51,
Olympus, Hamburg, Germany), using a 940 objective
(numerical aperture 0.65). BrdU-positive cells were coun-
ted within the muscle tissue from the proximal to the distal
insertion (*30 consecutive observation ﬁelds) and data
were given as cells per mm
2.
To determine apoptotic cell death cleaved caspase 3
staining was performed using a rabbit anti-cleaved caspase
3 (1:500, No. 9661, Cell Signaling Technology, Frankfurt,
Germany) antibody. 3,30-diaminobenzidine was used as
chromogen. Sections were analyzed by light microscopy
(BX 51, Olympus), using a 940 objective (numerical
aperture 0.65). Cleaved caspase 3 positive cells were
counted within the muscle tissue from the proximal to the
distal insertion (*30 consecutive observation ﬁelds) and
data were given as cells per mm
2.
To elucidate the coverage of muscle tissue we calculated
the muscle tissue area in percent to the entire observation
ﬁeld in entire hematoxylin–eosin (HE) stained tissue. For
the HE analysis tissue was stained in Mayer’s hemalum
solution, rinsed in 0.1% HCl, stained in Eosin solution, and
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density digital images of the entire muscle were acquired
by means of a digital camera (Colorview II, Olympus) and
planimetrically analyzed using Photoshop (Photoshop7,
Adobe Systems Europe, Uxbridge, UK). In the same sec-
tions we analyzed the muscle ﬁber diameter in 0.01 mm
2 of
the penumbra area (4 observation ﬁelds) using a 920
objective and the light microscopic imaging software Cell
D
(Olympus).
By manually clamping the left soleus muscle seven
times over its complete length we produced an inhomo-
geneous tissue injury with areas of complete distraction
and of moderate to almost no injury (‘‘penumbra’’) [18].
We started to count the positive cells from the proximal to
the distal insertion of the muscle disregarding the heter-
ogenous morphology of the muscle as previously described
by our group [18]. The complete loss of visible muscle
cells in the severely injured parts of muscle tissue did not
allow to express the positive cells per number of all muscle
cells in the observation ﬁeld. Quantitative analysis of
immunohistochemical and histological staining is thus
given as positive cells per mm
2.
Molecular biology
By means of Western blot we analyzed the protein
expression of B-cell lymphoma-2 protein (bcl-2) and bcl-2-
associated-X protein (bax). For this purpose, muscle tissue
was homogenized in lysis buffer (1 M Tris, pH 7.5, 5 M
NaCl, 250 mM EDTA, 10% Triton-9100, 4% NaN3, and
100 mM PMSF), incubated for 30 min on ice, and centri-
fuged for 15 min at 10,0009g. Before use, all buffers
received a protease inhibitor cocktail (1:100 vol/vol;
Sigma-Aldrich, Hamburg, Germany). Protein concentra-
tions were determined using the BCA protein assay (Pierce,
Rockford, IL) with bovine serum albumin as standard.
Protein extracts (40 lg) were separated discontinuously on
sodium dodecyl sulfate polyacrylamide gels (12% SDS-
PAGE) and transferred to a polyvinylidenediﬂuoride
membrane (Immobilon-P transfer membrane; Millipore,
Billerica, MA). After blockade of nonspeciﬁc binding sites
membranes were incubated for 2 h at room temperature
with primary antibodies followed by secondary antibodies
(primary bax antibody: 1:250, BD-556467, Becton–Dick-
inson, Franklin Lakes, NJ and secondary bax antibody:
1:20.000, A9044, Sigma-Aldrich; primary bcl-2 antibody:
1:500, BD-610538, Becton–Dickinson and secondary bcl-2
antibody: 1:20.000, A9044, Sigma-Aldrich; primary
ß-actin antibody: 1:20.000, A5441, Sigma-Aldrich and
secondary ß-actin antibody: 1:60.000, A9044, Sigma-
Aldrich). Protein expression was visualized by means of
luminol-enhanced chemiluminescence (ECL Plus; Amer-
sham Pharmacia Biotech, Freiburg, Germany), digitalized
with ChemiDocTM XRS System (Bio-Rad Laboratories,
Munich, Germany) and calculated in relation to the ß-actin
expression.
Experimental groups
Two experimental groups of animals were included in the
present study: z-VAD group, i.e. animals which underwent
crush injury of the left soleus muscle and received injection
of the pan-caspase inhibitor z-VAD.fmk (3.3 mg/kg b.w.
i.p.; z-VAD.fmk, Sigma-Aldrich Chemie GmbH, Ger-
many) at 0 and 48 h after injury; control group, i.e. animals
which underwent crush injury of the left soleus muscle and
received equivalent volumes of DMSO (1.0 ml/kg b.w.
DMSO i.p.) at 0 and 48 h after injury. Subsequent analysis
was performed 4 and 14 days after injury induction (n = 6
animals per time point and group).
Statistical analysis
All data are expressed as means ± standard error of the
mean (SEM). Differences between groups and time points
were assessed using an unpaired Student’s t-test. Statistical
signiﬁcance was set at P\0.05. Statistics were performed
using the GraphPad Prism 5.0 software (GraphPad Soft-
ware, San Rafael, CA).
Results
All animals that underwent open crush injury awoke from
anesthesia without complications. Usage of the left hind
limb was found only slightly reduced during the ﬁrst one to
three days. There were no other signs of discomfort or
illness. The operated extremity did not show macroscopic
signs of local infection or impaired wound healing in any
animal.
The use of this injury model induced both local damage
and serious functional impairment in the injured muscle,
which lasted up to 14 days after injury. As a result 4 days
upon muscle injury twitch force was found reduced in both
groups reaching mean values between 13 and 16% com-
pared to the force of the contralateral muscle (Fig. 1a;
P = 0.28). At the same time point corresponding mean
values of the tetanic force ranged between 16 and 25%
(Fig. 1b; P = 0.44). Interestingly, caspase inhibition med-
iated by injection of z-VAD.fmk enhanced the muscle force
at day 14, as given by a 1.6 fold increase of the twitch force
(P = 0.001) and a 1.3 fold escalation of the tetanic force
(P = 0.27) when compared to control (Fig. 1a and b).
Traumatized muscle tissue presented with a signiﬁcant
rise of the twitch-to-tetanic force ratio in both groups at day
4 after injury induction, indicating a transient switch to a
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123fast-twitching phenotype of muscle. In contrast to DMSO
treated animals maintaining the fast-twitching phenotype at
day 14, animals administered z-VAD.fmk showed already
a decrease in the twitch-to-tetanic force ratio, indicating an
enhanced turn back to the physiological phenotype of a
slow-twitching muscle [Table 1; left muscle (control vs.
z-VAD): P = 0.78 at day 4 and P = 0.05 at day 14; right
muscle (control vs. z-VAD): P = 0.18 at day 4 and
P = 0.82 at day 14; control group (right muscle vs. left
muscle): P = 0.03 at day 4 and P = 0.03 at day 14;
z-VAD group (right muscle vs. left muscle): P B 0.001 at
day 4 and P = 0.08 at day 14].
While muscle injury resulted in an increase of the
muscle cell proliferation 4 days after injury, the incorpo-
ration of BrdU into the injured muscle tissue was signiﬁ-
cantly reduced in the z-VAD.fmk group, indicating a
reduced need for proliferation (Fig. 2a and b; P = 0.04).
Regarding muscle cell proliferation after 14 days no sig-
niﬁcant difference could be observed between the z-VAD
and the control group (Fig. 2b; P = 0.37).
Administration of z-VAD.fmk almost completely abol-
ished cell death in the injured muscle at day 4 after injury.
Accordingly, quantitative analysis of cleaved caspase 3
positive cells at day 4 after muscle injury showed a sig-
niﬁcant decrease of apoptosis in the z-VAD group com-
pared to the control group (Fig. 3a and b; P B 0.001). At
day 14 the apoptotic cell rate decreased to 2–3 cells/mm
2
and no signiﬁcant differences between both groups was
observed (Fig. 3a and b; P = 0.69).
Western blot analysis for the expression of the pro- and
anti-apoptotic proteins bax and bcl-2 did not show any
difference between the groups (Table 2; bax/ß-actin:
P = 0.85 at day 4 and P = 0.43 at day 14; bcl-2/ß-actin:
P = 0.77 at day 4 and P = 0.86 at day 14). Similarly the
ratio of the pro- to anti-apoptotic proteins (bax/ß-actin to
bcl-2/ß-actin ratio) was not statistically signiﬁcant between
the z-VAD and the control group (Table 2; bax/ß-actin per
bcl-2/ß-actin: P = 0.59 at day 4 and P = 0.89 at day 14).
This implies that the use of z-VAD.fmk does not involve
the modulation of these proteins for its regenerative action
in muscle injury.
Enhancement of muscle functions upon pan-caspase
inhibition (Fig. 1a and b) was preceded by a signiﬁcant
increase of muscle tissue area at day 4 (Fig. 4b; P = 0.02)
and slightly higher values of muscle tissue at day 14 in the
z-VAD group compared to the control group (Fig. 4b;
P = 0.41). In addition, increased muscle cell diameter was
observed at day 14 in the z-VAD group, indicating that
caspase inhibition reduced muscle cell atrophy and induced
a relative muscle cell hypertrophy after muscle injury
(Fig. 5b; P = 0.45 at day 4 and P = 0.02 at day 14).
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Fig. 1 Twitch (a) and tetanic (b) force in animals which underwent a
standardized open crush injury to the left soleus muscle and treatment
with DMSO as vehicle solution (control white bars, n = 6 animals
per time point) or pan-caspase inhibitor z-VAD.fmk (z-VAD gray
bars, n = 6 animals per time point). Analysis was performed at days
4 and 14 after injury. Data are given as means ± SEM; t-test:
*P\0.05 vs control (refer text for exact P values)
Table 1 Twitch-to-tetanic force ratio of the right and left soleus muscle
Twitch-to-tetanic force ratio
Right (non-injured) muscle Left (injured) muscle
Day Control z-VAD Control z-VAD
4 0.49 ± 0.05 0.56 ± 0.01 0.70 ± 0.08
# 0.73 ± 0.05
#
14 0.48 ± 0.02 0.49 ± 0.03 0.74 ± 0.02
# 0.64 ± 0.04*
Animals underwent muscle injury and treatment with DMSO as vehicle solution (control) or pan-caspase inhibitor z-VAD.fmk (z-VAD).
Analysis was performed at day 4 and 14 after injury. Data are given as mean ± SEM; n = 6 per time point and group; t-test: *P\0.05 vs
control;
#P\0.05 versus right (non-injured) muscle (refer text for exact P values)
272 Apoptosis (2012) 17:269–277
123Discussion
Inhibition of caspase-mediated apoptosis supported the
functional restoration of the injured muscle by amplifying
the twitch and tetanic force. Furthermore z-VAD.fmk
promoted the survival of the injured myoﬁbers and
decreased muscle atrophy, as indicated by the increased
muscle tissue area. Thereby, the need for muscle cell
proliferation at day 4 seems to be reduced. This resulted
into a relative muscle cell hypertrophy at day 14 after
injury and an enhanced morphological switch towards a
slow-twitching phenotype of muscle.
Methodological considerations
Regarding the animal’s age, it is known that younger animals
experience a quicker regeneration than aged animals and old
animals sustain structural and functional changes of the
muscle, that lead to a reduced regenerative capacity [19].
Regarding the sex of the animals, it is postulated that female
rodents experienceaftermuscleinjury lesspronouncedtissue
damage compared to equally injured males [20]. The few
animal studies that have focused on gender differences after
muscle injury concluded that female hormones were at least
partially responsible for lower levels of muscle damage [21,
22]. Unfortunately, these experimental results in animals
could not be conﬁrmed by human studies after muscle injury,
as no signiﬁcant advantage in the recovery of females over
malescouldbenotedinthesetrials[23,24].Thoughthereisso
far no evidence that the caspase could have a sex speciﬁc
action in the skeletal muscle, there is evidence for gender
dependent cell death pathways in the ischemic brain. In line
with this, Liuetal. reportedthatcaspase dependent celldeath
pathwaysare preferentially activatedin thefemale brainafter
experimentalstrokeinductioninmice[25]andthatfemalebut
not male animals beneﬁt from caspase inhibition.
Caspase inhibition and muscle strength
A variety of diseases and degenerative disorders like can-
cer, sepsis, uremia, or diabetes that are associated with loss
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Fig. 2 Representative light microscopic images (a) of BrdU staining
(9400 magniﬁcation, arrows indicate BrdU positive cells) as well as
quantitative analysis of BrdU positive cells (b). Animals underwent a
standardized open crush injury to the left soleus muscle and treatment
with DMSO as vehicle solution (control, white bars, n = 6 animals
per time point) or pan-caspase inhibitor z-VAD.fmk (z-VAD gray
bars, n = 6 animals per time point). Analysis was performed at days
4 and 14 after injury. Data are given as means ± SEM; t-test:
*P\0.05 versus control (refer text for exact P values)
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Fig. 3 Representativelightmicroscopicimages(a)ofcleavedcaspase
3 staining (9400 magniﬁcation, arrows indicate cleaved caspase 3
positive cells) as well as quantitative analysis of cleaved caspase 3
positive cells (b). Animals underwent a standardized open crush injury
to the left soleus muscle and treatment with DMSO as vehicle solution
(control white bars, n = 6 animals per time point) or pan-caspase
inhibitor z-VAD.fmk (z-VAD; gray bars, n = 6 animals per time
point). Analysis was performed at days 4 and 14 after injury. Data are
given as means ± SEM; t-test: *P\0.05 vs control (refer text for
exact P values)
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123of muscle force are accompanied by caspase activation
[26]. Especially for muscle tissue the cell apoptosis is
considered a key phenomenon during the pathogenesis of
dystrophy, degeneration or injury. Interestingly, caspase
inhibition can improve skeletal muscle force capacity in
animal models of muscle disease [27–29]. In most of those
conditions, caspase activation is associated with cell death,
but there are few exceptions like the heart muscle where
caspase activation is the consequence of cellular dysfunc-
tion [27]. Communal et al. have previously reported that
caspase 3 cleaved myoﬁbrillar proteins in cardiac myo-
cytes, disturbing the physiological link between muscle
force and calcium concentration. As a consequence, inhi-
bition of caspase 3 was followed by increased muscle
strength in vitro [27]. Increased muscle strength was also
observed for skeletal muscle injury during apoptosis inhi-
bition by z-VAD.fmk in sepsis and endotoxin-induced
diaphragmatic weakness [28, 29]. Supinski and coworkers
reported that the increased caspase activity in rat
Table 2 Quantitative densitometric Western blot analysis of the pro-apoptotic bax and the anti-apoptotic bcl-2 per ß-actin protein expression in
soleus muscle tissue
bax/ß-actin bcl-2/ß-actin bax/ß-actin to bcl-2/ß-actin ratio
Day Control z-VAD Control z-VAD Control z-VAD
4 0.57 ± 0.03 0.56 ± 0.06 0.47 ± 0.06 0.50 ± 0.08 1.31 ± 0.18 1.18 ± 0.14
14 0.68 ± 0.05 0.74 ± 0.05 0.61 ± 0.09 0.63 ± 0.08 1.22 ± 0.16 1.25 ± 0.15
Animals underwent muscle injury and treatment with DMSO as vehicle solution (control) or pan-caspase inhibitor z-VAD.fmk (z-VAD).
Analysis was performed at day 4 and 14 after injury. Data are given as mean ± SEM; n = 6 per time point and group; t-test; no statistical
signiﬁcances were found
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Fig. 4 Representative light microscopic images (a) of HE staining
(9100 magniﬁcation) as well as quantitative analysis of muscle tissue
area (b). Animals underwent a standardized open crush injury to the
left soleus muscle and treatment with DMSO as vehicle solution
(control white bars, n = 6 animals per time point) or pan-caspase
inhibitor z-VAD.fmk (z-VAD gray bars, n = 6 animals per time
point). Analysis was performed at days 4 and 14 after injury. Data are
given as means ± SEM; t-test: *P\0.05 versus control (refer text
for exact P values)
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Fig. 5 Representative light microscopic images (a) of HE staining
(9400 magniﬁcation; double headed arrows indicate the myoﬁber
diameter) as well as quantitative analysis of muscle ﬁber diameter (b).
Animals underwent a standardized open crush injury to the left soleus
muscle and treatment with DMSO as vehicle solution (control white
bars, n = 6 animals per time point) or pan-caspase inhibitor
z-VAD.fmk (z-VAD gray bars, n = 6 animals per time point).
Analysis was performed at days 4 and 14 after injury. Data are given
as means ± SEM; t-test: *P\0.05 vs control (refer text for exact
P values)
274 Apoptosis (2012) 17:269–277
123diaphragm during catabolic procedures is associated with a
reduction in force generation [28]. The authors could fur-
ther demonstrate that the z-VAD.fmk-associated increase
of muscle strength in endotoxin-induced diaphragmatic
weakness was mediated by the inhibition of the degrada-
tion of the cytoskeletal protein alpha-spectrin, which is
important in maintaining cellular integrity [28]. Similar
reports are published for the heart muscle, where the pan-
caspase inhibitor z-VAD.fmk reduced endotoxin-induced
heart dysfunction and boosted the systolic performance of
the left ventricle [30, 31]. In summary, current literature
support our data and our primary assumption that caspase
inhibition increases muscle strength and thereby augments
muscle regeneration.
Skeletal muscles have a well-deﬁned plasticity. Under
certain conditions, myosin heavy chain isoforms change
their protein structure, heading in the direction of either
fast-to-slow or slow-to-fast twitching phenotype. Increased
neuromuscular activity, mechanical loading, or hypothy-
roidism induces a fast-to-slow transition. On the contrary,
reduced neuromuscular activity, trauma, mechanical
unloading, muscular atrophy, or hyperthyroidism cause
transitions into the slow-to-fast direction [32]. This mor-
phological switch of myosin heavy chain isoforms can
indirectly be veriﬁed by calculation of the twitch-to-tetanic
force ratio [9]. In the current experiments muscle injury
caused a transient switch towards a fast-twitching pheno-
type. This phenotypic switch was less pronounced 14 days
after muscle injury in the z-VAD group, probably reﬂecting
a better and faster transformation of the injured muscle
towards the normal slow-twitching phenotype.
Molecular basis of apoptosis inhibition, muscle cell
hypertrophy and atrophy
Hypertrophic events after apoptosis inhibition have been
described in smooth muscle cells. In support to our results,
Marchand et al. described that z-VAD.fmk blocked losar-
tan-induced smooth muscle cell death and vascular
remodeling in spontaneously hypertensive rats [33].
Members of the caspase protein family do play a crucial
role not only during apoptotic and degenerative events but
also during muscle cell atrophy and hypertrophy. Particu-
larly, caspases have been identiﬁed to participate in muscle
atrophy during the initial step by myoﬁbrillar proteolysis
and cleavage of actomyosin [34]. As a result, Du et al.
stated that inhibition of caspase activation could be a
potential therapeutic target during katabolic events, trauma
and disease [35]. On the contrary, continuing evidence
exists that inhibition of caspase cleavage results into
muscle hypertrophy. In support of that Hu et al. reported
that transgenic mice, which selectively express the
endogenous caspase inhibitor X-chromosome-linked
inhibitor of apoptosis protein (XIAP) in skeletal muscles,
have hypertrophic peripheral muscles compared to wild-
type animals [36]. The role of anti-apoptotic processes
during hypertrophy has been further highlighted by Siu
et al., reporting that muscle cell hypertrophy induced by
stretch overload of the patagialis muscle in birds up-regu-
lates XIAP [37]. Caspase activity has also been associated
with regenerative and proliferative processes. Moresis et al.
postulated that inhibition of caspase activity improved
muscle recovery, assuming ﬁrstly a non-apoptotic role for
this pathway in the myogenic program and secondly that
the caspase activity is necessary for the TNF-dependent
inhibition of myogenesis in vivo [38]. The group could also
show that the pan-caspase inhibitor z-VAD.fmk increased
the number of regenerating myoﬁbers after freeze injury in
rats [38].
The ratio of bax and bcl-2 is indicative for mitochon-
drial-induced apoptosis, because bcl-2 opposes the pro-
apoptotic activity of bax by preventing its translocation to
the mitochondria [39]. Additionally, the ratio bax to bcl-2
regulate myonuclei cell survival by controlling mitochon-
drial membrane stability [40]. As a result disbalance
between anti-apoptotic proteins and pro-apoptotic proteins
induces the formation of permeable membrane pores and
stimulates the mitochondrial driven apoptosis [41]. Con-
sidering the fact, that no signiﬁcant difference in the bax to
bcl-2 ratio was observed in the presented study it is rea-
sonable to postulate that z-VAD.fmk does not inﬂuence the
mitochondrial driven apoptosis at least in the current injury
model, but is able to enhance muscle cell regeneration
predominantly via its direct action on the caspase protein
family.
A variety of intracellular molecules have been identiﬁed
to impede apoptosis. The inhibitors of apoptosis proteins
(IAPs) are structurally and functionally related polypep-
tides that serve as endogenic apoptosis inhibitors. From a
molecular point of view z-VAD.fmk reduces the degrada-
tion of the IAP protein family in human cells after apop-
tosis induction in vitro [42, 43]. It has also been reported
that a member of the IAPs family that is termed BRUCE
(baculovirus IAP repeat ubiquitin-conjugating enzyme)
plays a predominant role in the inhibition of the apoptosis
cascade [44]. In addition, Bartke et al. described that the
pan-caspase inhibitor z-VAD.fmk completely blocked
BRUCE fragmentation in vitro after apoptosis induction of
human cervical cancer cells [43]. Other groups have sim-
ilarly analyzed the role of BRUCE during apoptosis inhi-
bition. Jansen and coworkers have recently reported that
prostaglandin F2a promotes muscle cell survival and
decreases muscle cell death in a BRUCE dependent way
[45]. In accordance with our results Jansen et al. showed
that apoptosis inhibition, induced by prostaglandin F2a up-
regulated BRUCE expression, resulted in decreased muscle
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123cell proliferation and larger myotubes [45]. All that data
provide major body of evidence, that the caspase cascade
inﬂuences the regeneration of injured muscle and that one
of the potential pathways of actions could be the modula-
tion of IAP expression.
Future perspectives
Current experiments identiﬁed the pan-caspase inhibitor
z-VAD.fmk as a potential therapeutic target to enhance
muscle regeneration following injury. Altogether our data
support the concept that therapies, that modulate the pro-
grammed cell death by suppressing apoptosis, could
potentially represent a promising clinical approach to cure
muscle tissue after injury. Under this point of view future
studies are needed to investigate how inhibitors of caspase
can be safely applied to patients in order to prevent muscle
dysfunction upon muscle injury and regeneration.
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